Literature DB >> 28547117

Non-Hypervascular Hypointense Nodules at Gadoxetic Acid MRI: Hepatocellular Carcinoma Risk Assessment with Emphasis on the Role of Diffusion-Weighted Imaging.

Chiara Briani1, Marco Di Pietropaolo2, Massimo Marignani3, Francesco Carbonetti2, Paola Begini3, Vincenzo David2, Elsa Iannicelli2.   

Abstract

INTRODUCTION AND AIM: In cirrhotic patients, the characterization of hypovascular nodules, hypointense on hepatobiliary phase gadoxetic acid disodium-enhanced magnetic resonance images (Gd-EOB-DTPA-enhanced MRI), is essential to look for the proper approach strategy. Our objective was to evaluate the imaging features and risk assessment of hypovascular nodules, hypointense on Gd-EOB-DTPA-enhanced MRI, focusing on the diagnostic value of diffusion-weighted imaging (DWI).
MATERIAL AND METHODS: This prospective study includes 35 patients with 50 hypovascular hypointense nodules. Signal intensity on T2-weighted images and DWI, vascular pattern on dynamic contrast-enhanced MRI and on hepatobiliary phase, and volume doubling time were analyzed for each nodule as well as patient's clinical features. Univariate and multivariate analyses were made to determine the variables associated with the development of hypervascular pattern.
RESULTS: On 24 months follow-up period, 40% of the hypointense nodules (mean size 14 mm ± 6.1) became hypervascular hepatocellular carcinoma (HCC) with 6 and 12 months cumulative risk of 45 and 55%. Nine/12 (75%, mean size 15.50 mm ± 7.2) that appeared hyperintense in DWI at first exam show malignant transformation (p value = 0.007). Univariate and multivariate analyses identified hyperintensity at initial DWI (OR 6.49; 95% CI 1.28-32.80; p value = 0.009) and size ≥10 mm (OR 6.22; 95% CI 1.57-24.63; p value = 0.024) as independent factors with the development of HCC.
CONCLUSION: In conclusion, hypovascular lesions ≥10 mm and those hyperintense in DWI were associated with progression to hypervascular HCC. A close follow-up or histological characterization is recommended to improve patients outcome and to develop effective treatment.

Entities:  

Keywords:  Diffusion-weighted imaging; Hepatocarcinogenesis; Hepatocellular carcinoma; Liver cirrhosis; MR imaging

Mesh:

Substances:

Year:  2018        PMID: 28547117     DOI: 10.1007/s12029-017-9952-7

Source DB:  PubMed          Journal:  J Gastrointest Cancer


  39 in total

Review 1.  Diffusion-weighted MR imaging of the liver.

Authors:  Bachir Taouli; Dow-Mu Koh
Journal:  Radiology       Date:  2010-01       Impact factor: 11.105

Review 2.  Gd-EOB-DTPA-Enhanced Magnetic Resonance Findings of a Giant Inflammatory Hepatocellular Adenoma: a Case Report and Review of the Literature.

Authors:  Marco Di Pietropaolo; Chiara Briani; Emanuela Pilozzi; Francesco Carbonetti; Vincenzo David; Elsa Iannicelli
Journal:  J Gastrointest Cancer       Date:  2015-12

3.  Imaging surveillance and multidisciplinary review improves curative therapy access and survival in HCC patients.

Authors:  Ron C Gaba; Eric R Kallwitz; Ahmad Parvinian; James T Bui; Natasha M Von Roenn; Jamie L Berkes; Scott J Cotler
Journal:  Ann Hepatol       Date:  2013 Sep-Oct       Impact factor: 2.400

4.  Recent advances in estimating hepatic functional reserve in patients with chronic liver damage.

Authors:  Satoru Imura; Mitsuo Shimada; Tohru Utsunomiya
Journal:  Hepatol Res       Date:  2014-04-24       Impact factor: 4.288

5.  New MR imaging criteria with a diffusion-weighted sequence for the diagnosis of hepatocellular carcinoma in chronic liver diseases.

Authors:  Gilles Piana; Ludovic Trinquart; Nawel Meskine; Vincent Barrau; Bernard Van Beers; Valérie Vilgrain
Journal:  J Hepatol       Date:  2010-11-23       Impact factor: 25.083

6.  Gd-EOB-DTPA-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading and portal blood flow.

Authors:  Sachiyo Kogita; Yasuharu Imai; Masahiro Okada; Tonsok Kim; Hiromitsu Onishi; Manabu Takamura; Kazuto Fukuda; Takumi Igura; Yoshiyuki Sawai; Osakuni Morimoto; Masatoshi Hori; Hiroaki Nagano; Kenichi Wakasa; Norio Hayashi; Takamichi Murakami
Journal:  Eur Radiol       Date:  2010-05-19       Impact factor: 5.315

7.  Hypovascular hepatic nodules showing hypointense on the hepatobiliary-phase image of Gd-EOB-DTPA-enhanced MRI to develop a hypervascular hepatocellular carcinoma: a nationwide retrospective study on their natural course and risk factors.

Authors:  Tatsuo Inoue; Tomoko Hyodo; Takamichi Murakami; Yukihisa Takayama; Akihiro Nishie; Atsushi Higaki; Keiko Korenaga; Azusa Sakamoto; Yukio Osaki; Hiroshi Aikata; Kazuaki Chayama; Takeshi Suda; Toru Takano; Kennichi Miyoshi; Masahiko Koda; Kazushi Numata; Hironori Tanaka; Hiroko Iijima; Hironori Ochi; Masashi Hirooka; Yasuharu Imai; Masatoshi Kudo
Journal:  Dig Dis       Date:  2013-11-21       Impact factor: 2.404

8.  Early hepatocellular carcinoma as an entity with a high rate of surgical cure.

Authors:  T Takayama; M Makuuchi; S Hirohashi; M Sakamoto; J Yamamoto; K Shimada; T Kosuge; S Okada; K Takayasu; S Yamasaki
Journal:  Hepatology       Date:  1998-11       Impact factor: 17.425

Review 9.  JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan.

Authors:  Masatoshi Kudo; Osamu Matsui; Namiki Izumi; Hiroko Iijima; Masumi Kadoya; Yasuharu Imai; Takuji Okusaka; Shiro Miyayama; Kaoru Tsuchiya; Kazuomi Ueshima; Atsushi Hiraoka; Masafumi Ikeda; Sadahisa Ogasawara; Tatsuya Yamashita; Tetsuya Minami; Koichiro Yamakado
Journal:  Liver Cancer       Date:  2014-10       Impact factor: 11.740

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  1 in total

Review 1.  Recent advances in non-invasive magnetic resonance imaging assessment of hepatocellular carcinoma.

Authors:  Davide Ippolito; Riccardo Inchingolo; Luigi Grazioli; Silvia Girolama Drago; Michele Nardella; Marco Gatti; Riccardo Faletti
Journal:  World J Gastroenterol       Date:  2018-06-21       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.